Mantle
- Total Funding$13 M
OverviewSuggest Edit
Mantle (formerly known as NanoCore) is a company that offers precision metal 3D printing for the tooling industry. Its machine builds part finishing into the process. The company caters to automotive, aerospace, consumer product design, and prototyping businesses.
| Type | Private | |
| Founded | 2015 | |
| HQ | San Francisco, CA, US | Map |
| Website | mantle3d.com |
Recent NewsAll News
- Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
- Benefit of Adding Ibrutinib to Bendamustine/Rituximab as Frontline Treatment for Mantle Cell Lymphoma: First Phase III Trial Changing the Paradigm for the Care of Elderly Patients
- Mantle – Serverless Maps Using Lambda or Cloudflare Workers
- JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
Latest Updates
| Employees (est.) (Jun 2022) | 41 | (+11%) |
| Cybersecurity rating | B | More |
Key People/Management at Mantle
Ted Sorom
Co-Founder and Chief Executive Officer
Steve Connor
Co-Founder and Chief Science Officer
Alex Goldenberg
Chief Technology Officer
Paul Dilaura
Chief Commercial Officer
Kimberlee Hayashi
Director of Process Development
Dana McCallum
Vice President of Sales
Mantle Office Locations
Mantle has an office in San Francisco
San Francisco, CA, US (HQ)
550 10th St, San Francisco
Mantle Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Mantle total Funding | $13 m |
Mantle latest funding size | $13 m |
Time since last funding | a year ago |
Mantle investors | Foundation Capital, Corazon Capital, Plug and Play, 11.2 Capital, Future Shape, Hypertherm Ventures |
Mantle's latest funding round in February 2021 was reported to be $13 m. In total, Mantle has raised $13 m
Mantle Cybersecurity Score
Mantle Online and Social Media Presence
98 Twitter followers
Mantle has 98 Twitter Followers. The number of followers has increased 1% month over month and increased 16.3% quarter over quarter
Mantle's Trends
Twitter Engagement Stats for @mantle3d
107
Tweets
19
Following
98
Followers
4
Tweets last 30 days
1
Avg. likes per Tweet
75%
Tweets with engagement
Mantle News and Updates
June 03, 2022
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Primary results from the first frontline Phase 3 study of a Bruton's tyrosine kinase inhibitor in MCL to be presented as late-breaking data at the 2022 ASCO Annual Meeting and also published in The New England Journal of Medicine CHICAGO, June 3, 2022 /PRNewswire/ -- The Janssen...
June 03, 2022
Benefit of Adding Ibrutinib to Bendamustine/Rituximab as Frontline Treatment for Mantle Cell Lymphoma: First Phase III Trial Changing the Paradigm for the Care of Elderly Patients
John Theurer Cancer Center Investigators Participate in Large Pivotal International Study HACKENSACK, N.J., June 3, 2022 /PRNewswire/ -- Hackensack Meridian John Theurer Cancer Center investigators participated in the large phase III multicenter SHINE study, which reported that using the...
April 03, 2022
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products...
March 06, 2022
Banks Investing In Russia Cannot Cloak Themselves In The ESG Mantle
Bank executives cannot brag about ESG adherence, while they are doing business with or in Russia. It is more than high time that banks walk the walk with ESG.
January 04, 2022
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration…
Mantle Frequently Asked Questions
When was Mantle founded?
Mantle was founded in 2015.
Who are Mantle key executives?
Mantle's key executives are Ted Sorom, Steve Connor and Alex Goldenberg.
How many employees does Mantle have?
Mantle has 41 employees.
Who are Mantle competitors?
Competitors of Mantle include Woodland Trade, C&A Tool and MX3D.
Where is Mantle headquarters?
Mantle headquarters is located at 550 10th St, San Francisco, San Francisco.
Where are Mantle offices?
Mantle has an office in San Francisco.
How many offices does Mantle have?
Mantle has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies